Advanced search
Publication Cover
Current Medical Research and Opinion Volume 23, 2007 - Issue 1
Submit an article Journal homepage
249
Views
16
CrossRef citations to date
0
Altmetric
Research Letter

Strategies to improve tolerability of rivastigmine: a case series

K. Venkatesh Victoria Hospital, Swindon, UKCorrespondence[email protected]
,
R. Bullock Victoria Hospital, Swindon, UK
&
A. Akbas¸ Samsun Mehmet Aydin State Hospital, Samsun, Turkey
Pages 93-95 | Accepted 24 Nov 2006, Published online: 07 Dec 2006

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Taher Darreh-Shori & Vesna Jelic. (2010) Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Expert Opinion on Drug Safety 9:1, pages 167-176.
Read now

Articles from other publishers (15)

Fahad Saad Alhodieb, Mohammad Akhlaquer Rahman, Muhammad Abul Barkat, Abdulkareem A Alanezi, Harshita Abul Barkat, Hazrina Ab Hadi, Ranjit K Harwansh & Vineet Mittal. (2023) Nanomedicine-driven therapeutic interventions of autophagy and stem cells in the management of Alzheimer's disease. Nanomedicine 18:2, pages 145-168.
Crossref
Mukta Agrawal, Upal Roy & Amit Alexander. 2023. Nanomedicine-Based Approaches for the Treatment of Dementia. Nanomedicine-Based Approaches for the Treatment of Dementia 149 168 .
Smita P. Borkar & Abhay Raizaday. 2023. Nasal Drug Delivery. Nasal Drug Delivery 361 379 .
Margarita E. Neganova, Yulia R. Aleksandrova, Olga A. Sukocheva & Sergey G. Klochkov. (2022) Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders. Seminars in Cancer Biology 86, pages 805-833.
Crossref
Zhenzhen Yang. 2021. Liposome-Based Drug Delivery Systems. Liposome-Based Drug Delivery Systems 325 344 .
Barnabas Wilson & Kannoth Mukundan Geetha. (2020) Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease. Journal of Controlled Release 325, pages 25-37.
Crossref
Mukta Agrawal, Swarnlata Saraf, Shailendra Saraf, Sophia G. Antimisiaris, Mahavir Bhupal Chougule, Sunday A. Shoyele & Amit Alexander. (2018) Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Journal of Controlled Release 281, pages 139-177.
Crossref
Zhenzhen Yang. 2019. VDI-Wärmeatlas. VDI-Wärmeatlas 1 20 .
Mukta Agrawal, Ajazuddin, Dulal K. Tripathi, Swarnlata Saraf, Shailendra Saraf, Sophia G. Antimisiaris, Spyridon Mourtas, Margareta Hammarlund-Udenaes & Amit Alexander. (2017) Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease. Journal of Controlled Release 260, pages 61-77.
Crossref
Zhen-Zhen Yang, Yan-Qing Zhang, Zhan-Zhang Wang, Kai Wu, Jin-Ning Lou & Xian-Rong Qi. (2013) Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. International Journal of Pharmaceutics 452:1-2, pages 344-354.
Crossref
R. Blesa González, M. Boada Rovira, C. Martínez Parra, D. Gil-Saladié, C.A. Almagro & A.L. Gobartt Vázquez. (2011) Evaluación de la conveniencia del cambio de vía de administración de rivastigmina en pacientes con enfermedad de Alzheimer. Neurología 26:5, pages 262-271.
Crossref
Gary Small & Roger Bullock. (2010) Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. Alzheimer's & Dementia 7:2, pages 177-184.
Crossref
R. Blesa González, M. Boada Rovira, C. Martínez Parra, D. Gil-Saladié, C.A. Almagro & A.L. Gobartt Vázquez. (2011) Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease. Neurología (English Edition) 26:5, pages 262-271.
Crossref
. (2007) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 22:10, pages 1055-1062.
Crossref
. (2007) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 16:8, pages i-xii.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.